FDA in final stages before issuing Pfizer, BioNTech EUA

By The Science Advisory Board staff writers

December 11, 2020 -- The U.S. Food and Drug Administration (FDA) has informed Pfizer and BioNTech that it will work rapidly toward the finalization and issuance of an emergency use authorization (EUA) for the company's COVID-19 vaccine candidate.

The statement was given by Dr. Stephen Hahn, the FDA commissioner and Dr. Peter Marks, PhD, the director of the Center for Biologics Evaluation and Research, following the December 10 meeting of the Vaccines and Related Biologicals Products Advisory Committee (VRBPAC), which produced a positive outcome.

In addition to notifying the sponsors, the FDA also notified the U.S. Centers for Disease Control and Prevention and Operation Warp Speed so that execution of plans for a timely vaccine distribution can begin.

Copyright © 2020 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here